WASHINGTON — The American Pharmacists Association announced Thursday that its House of Delegates had voted to adopt a new policy concerning labeling and measuring of oral liquid medications at the APhA Annual Meeting in Baltimore, Md.
The American Pharmacists Association has shown support for the new guideline encouraging physicians to first turn to non-opioid treatment for chronic pain outside cancer-related pain, palliative treatment and end-of-life care.
Like a powerful tide that gradually eats away at the foundations of a once-impregnable sea wall, the booming market for generic drugs advances and recedes with the rise and fall in the number of branded drug patent expirations each year. Download the full Generic Drug Report 2016 to read more.
Reuters is reporting that Teva is expecting for its acquisition of Allergan’s generic drug unit — a deal valued at $40.5 billion — to be complete by June. Currently it is makign progress, receiving approval from the European Commission and awaiting approval from the Federal Trade Commission. (Reuters)
Increasingly, states are looking to address the prescription painkiller problem with as many as 375 proposals coursing through state legislatures that would regulated pain clinics and prescribing painkillers, The New York Times reported Friday. "The states are going to lead on this one because Big Pharma has too much power," Vermont Gov. Peter Shumlin, Democrat, told The New York Times. The New York Times added: "The pace of [legislative] activity in states has grown so intense that experts are having difficulty keeping track." (The New York Times)
Teva on Thursday became the first company to get U.S. approval for its generic Viagra from the Food and Drug Administration. Regulatory Focus is reporting that according to Teva, the erectile dysfunction generic will start being marketed in December 2017, due to a settlement the company reached with Pfizer, which makes Viagra. The drug was approved in 25- 50- and 100-mg dosage strengths. (Regulatory Focus)
“Better care, smarter spending, healthier people.” Those were the goals set forth by the Centers for Medicare and Medicaid Services in September when it unveiled plans for a five-year federal experiment to gauge the effectiveness of expanded medication therapy management for Medicare patients.
Like a powerful tide that gradually eats away at the foundations of a once-impregnable sea wall, the booming market for generic drugs advances and recedes with the rise and fall in the number of branded drug patent expirations each year.
As part of its annual Industry Issues Conference in December, Drug Store News assembled a first-class panel of retail pharmacy and supplier executives for an exclusive, in-depth discussion on emerging best practices for improving care among patients with chronic conditions.
The future of American health care could be summed up in one word — “connection.” To thrive in a fast-reforming healthcare system that demands better patient outcomes at a lower cost, pharmacies, physicians, hospitals, health systems, outpatient clinicians and diagnosticians are going to have to connect much more effectively, both with one another and with the patients they serve.
Going back at least to the mid-1800s, many community pharmacists have been given the informal title of “doc” or “doctor” by grateful local residents, particularly in smaller towns and rural communities where the local pharmacist might be the only health provider within miles. These days, the title is more than honorary; it’s a requirement.